Table 2. Changes in RA and Sal B accumulations by transgenic lines under MeJA treatment.

Line	Condition	RA (mg g−1DW)	Sal B (mg g−1DW)
Control	MOCK	29.33 ± 0.65	11.43 ± 0.37
	MeJA	41.98 ± 0.65**	16.97 ± 0.21**
OEB-5	MOCK	33.29 ± 2.12	15.92 ± 0.95
	MeJA	36.29 ± 2.29	15.82 ± 1.03
OEB-7	MOCK	27.52 ± 2.00	9.67 ± 0.54
	MeJA	31.02 ± 0.99	13.87 ± 0.21*

*significant at p < 0.05; **highly significant at p < 0.01.